J Boban1, D Kozic2, V Turkulov3, D Lendak3, M Bjelan2, M Semnic4, S Brkic3. 1. From the Faculty of Medicine (J.B., D.K., M.B.), University of Novi Sad, Vojvodina Institute of Oncology, Diagnostic Imaging Center, Novi Sad, Serbia jasmina.boban@mf.uns.ac.rs. 2. From the Faculty of Medicine (J.B., D.K., M.B.), University of Novi Sad, Vojvodina Institute of Oncology, Diagnostic Imaging Center, Novi Sad, Serbia. 3. Faculty of Medicine (V.T., D.L., S.B.), University of Novi Sad, Clinical Center of Vojvodina, Clinic for Infectious Diseases, Novi Sad, Serbia. 4. Faculty of Medicine (M.S.), University of Novi Sad, Clinical Center of Vojvodina, Clinic for Neurology, Novi Sad, Serbia.
Abstract
BACKGROUND AND PURPOSE: The introduction of combination antiretroviral therapy has failed to reduce the high prevalence of mild forms of HIV-associated neurocognitive disorders. The aim of this study was to test the effect of combined antiretroviral therapy on brain metabolite ratios in chronic HIV infection by using proton chemical shift imaging. MATERIALS AND METHODS: We performed 2D chemical shift imaging in 91 subjects (31 HIV+ patients with chronic infection on combination antiretroviral therapy, 19 combination antiretroviral therapy-naïve HIV+ subjects with chronic infection, and 41 healthy controls), covering frontal and parietal subcortical white and cingulate gyrus gray matter, analyzing ratios of NAA/Cr and Cho/Cr on long-TE and mIns/Cr on short-TE MR spectroscopy. We correlated neurometabolic parameters with immunologic, clinical, data and combined antiretroviral therapy efficacy scores. RESULTS: There was a significant decrease in NAA/Cr (P < .05) in HIV-positive patients on and without combined antiretroviral therapy, compared with healthy controls in all locations. There were significant differences in Cho/Cr (P < .05) and mIns/Cr (P < .05) ratios between HIV+ patients on and without therapy, compared with healthy controls, but these differed in distribution. There were no significant differences in brain metabolite ratios between the 2 groups of chronically HIV-infected patients. The CNS penetration efficacy score showed weak positive correlations only with Cho/Cr ratios in some locations. CONCLUSIONS: The impact of combined antiretroviral therapy on the process of neuronal loss and dysfunction in chronic HIV infection appears to be suboptimal in successful peripheral suppression of viral replication. Spectroscopic imaging might be a useful tool for monitoring the effects of different combined antiretroviral therapy regimens on brain metabolite ratios.
BACKGROUND AND PURPOSE: The introduction of combination antiretroviral therapy has failed to reduce the high prevalence of mild forms of HIV-associated neurocognitive disorders. The aim of this study was to test the effect of combined antiretroviral therapy on brain metabolite ratios in chronic HIV infection by using proton chemical shift imaging. MATERIALS AND METHODS: We performed 2D chemical shift imaging in 91 subjects (31 HIV+ patients with chronic infection on combination antiretroviral therapy, 19 combination antiretroviral therapy-naïve HIV+ subjects with chronic infection, and 41 healthy controls), covering frontal and parietal subcortical white and cingulate gyrus gray matter, analyzing ratios of NAA/Cr and Cho/Cr on long-TE and mIns/Cr on short-TE MR spectroscopy. We correlated neurometabolic parameters with immunologic, clinical, data and combined antiretroviral therapy efficacy scores. RESULTS: There was a significant decrease in NAA/Cr (P < .05) in HIV-positivepatients on and without combined antiretroviral therapy, compared with healthy controls in all locations. There were significant differences in Cho/Cr (P < .05) and mIns/Cr (P < .05) ratios between HIV+ patients on and without therapy, compared with healthy controls, but these differed in distribution. There were no significant differences in brain metabolite ratios between the 2 groups of chronically HIV-infectedpatients. The CNS penetration efficacy score showed weak positive correlations only with Cho/Cr ratios in some locations. CONCLUSIONS: The impact of combined antiretroviral therapy on the process of neuronal loss and dysfunction in chronic HIV infection appears to be suboptimal in successful peripheral suppression of viral replication. Spectroscopic imaging might be a useful tool for monitoring the effects of different combined antiretroviral therapy regimens on brain metabolite ratios.
Authors: Ronald A Cohen; Jaroslaw Harezlak; Giovanni Schifitto; George Hana; Uraina Clark; Assawin Gongvatana; Robert Paul; Michael Taylor; Paul Thompson; Jeffery Alger; Mark Brown; Jianhui Zhong; Thomas Campbell; Elyse Singer; Eric Daar; Deborah McMahon; Yuen Tso; Constantin T Yiannoutsos; Bradford Navia Journal: J Neurovirol Date: 2010-02 Impact factor: 2.643
Authors: Desiree A Byrd; Robert P Fellows; Susan Morgello; Donald Franklin; Robert K Heaton; Reena Deutsch; J Hampton Atkinson; David B Clifford; Ann C Collier; Christina M Marra; Benjamin Gelman; J Allen McCutchan; Nichole A Duarte; David M Simpson; Justin McArthur; Igor Grant Journal: J Acquir Immune Defic Syndr Date: 2011-10-01 Impact factor: 3.731
Authors: David F Tate; Mehul Sampat; Jaroslaw Harezlak; Mark Fiecas; Joseph Hogan; Jeffrey Dewey; Daniel McCaffrey; Daniel Branson; Troy Russell; Jared Conley; Michael Taylor; Giovanni Schifitto; Giavoni Schifitto; J Zhong; Eric S Daar; Jeffrey Alger; Mark Brown; Elyse Singer; T Campbell; D McMahon; Y Tso; Janetta Matesan; Scott Letendre; S Paulose; Michelle Gaugh; C Tripoli; Constantine Yiannoutsos; Erin D Bigler; Ronald A Cohen; Charles R G Guttmann; Bradford Navia Journal: J Neurovirol Date: 2011-05-10 Impact factor: 2.643
Authors: Cecilia M Shikuma; Beau Nakamoto; Bruce Shiramizu; Chin-Yuan Liang; Victor DeGruttola; Kara Bennett; Robert Paul; Kalpana Kallianpur; Dominic Chow; Christina Gavegnano; Selwyn J Hurwitz; Raymond F Schinazi; Victor G Valcour Journal: Antivir Ther Date: 2012-09-28
Authors: Napapon Sailasuta; William Ross; Jintanat Ananworanich; Thep Chalermchai; Victor DeGruttola; Sukalaya Lerdlum; Mantana Pothisri; Edgar Busovaca; Silvia Ratto-Kim; Linda Jagodzinski; Serena Spudich; Nelson Michael; Jerome H Kim; Victor Valcour Journal: PLoS One Date: 2012-11-16 Impact factor: 3.240
Authors: Junran Cao; Shaolin Wang; Ju Wang; Wenyan Cui; Tanseli Nesil; Michael Vigorito; Sulie L Chang; Ming D Li Journal: PLoS One Date: 2013-07-16 Impact factor: 3.240
Authors: Jasmina M Boban; Dusko B Kozic; Snezana V Brkic; Dajana F Lendak; Majda M Thurnher Journal: Front Aging Neurosci Date: 2018-10-18 Impact factor: 5.750
Authors: R Gilberto González; Robert Fell; Julian He; Jennifer Campbell; Tricia H Burdo; Patrick Autissier; Lakshmanan Annamalai; Faramarz Taheri; Termara Parker; Jeffrey D Lifson; Elkan F Halpern; Mark Vangel; Eliezer Masliah; Susan V Westmoreland; Kenneth C Williams; Eva-Maria Ratai Journal: PLoS One Date: 2018-05-11 Impact factor: 3.240